Also known as: 39EVI31P0W, RefChem:110496, 141925-59-9, Alanyl-histidyl-(2-naphthyl)alanyl-tryptophyl-phenylalanyl-lysinamide, L-Alanyl-L-histidyl-3-(2-naphthalenyl)-D-alanyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-lysinamide, (2S)-6-amino-2-[(2R)-2-[(2S)-2-[(2S)-2-[(2R)-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-(1H-imidazol-4-yl)propanamido]-3-(naphthalen-2-yl)propanamido]propanamido]-3-(1H-indol-3-yl)propanamido]-3-phenylpropanamido]hexanamide, GHRP 1, UNII-39EVI31P0W
GHRP-1 (39EVI31P0W, RefChem:110496, 141925-59-9) is classified under ghrelin / gh secretagogues, sold for research use only and not approved for human consumption.
Aggregated from the cited literature below. We summarize sources — we don't author claims.
GHRP-1 is described in the provided sources as a synthetic growth hormone (GH)–releasing peptide (GHRP) tested for effects on GH secretion. In vitro work using ovine pituitary cells reported increased GH secretion with GHRP-1 (KP 101). Other provided sources discuss GHRPs in general as synthetic peptides that stimulate GH release and have been studied in animals and humans via routes including intravenous and oral administration (sources describe GHRP-1 among others). Anti-doping and analytical studies assessed detection of GHRP-1 and its metabolites in urine after nasal administration and reported identification of multiple metabolites but no parent GHRP-1 in the parent form in that study’s urine samples. (PMIDs: 8049717, 9186261, 25869809, 9465289, 8374685, 8950613, 24574167, 8496311, 8950613)
Mechanism (as reported)
In vitro research in primary ovine pituitary cells reported that calcium-channel blockade with Cd2+ abolished the GH-releasing effects of KP 101 (GHRP-1) as well as GHRP-6 and GRF. The same in vitro study reported that the GHRP-1–induced GH release was not affected by a GRF antagonist ([Ac-Tyr1, D-Arg2]-GRF 1-29). Additional review-style sources state that GHRPs act via specific receptors at the pituitary and/or hypothalamic level, are non-structurally homologous to GHRH, and that the mechanism remains unclear, with hypotheses involving counteracting somatostatinergic activity and/or GHRH-mediated mechanisms, including the possibility of an unknown hypothalamic factor. (PMIDs: 8049717, 9186261, 9465289, 5, 8, 8950613)
Key findings (each cites a source)
In vitro perifusion of primary ovine pituitary cells, research reported that GHRP-1 (KP 101) increased growth hormone (GH) secretion in a dose-dependent manner and that its half-maximal effective dose was reported as 10(-7) M in that study. (PMIDs: 8049717) [PMID 8049717]
In the same in vitro study, blockade of calcium channels with Cd2+ (2 mM) reportedly totally and reversibly abolished the releasing effects of KP 101 (GHRP-1), GHRP-6, and GRF. (PMIDs: 8049717) [PMID 8049717]
The in vitro study reported that GRF antagonist ([Ac-Tyr1, D-Arg2]-GRF 1-29, 1 microM) significantly reduced GRF effects on GH release but did not affect the GH release induced by KP 101 (GHRP-1). (PMIDs: 8049717) [PMID 8049717]
In urine after nasal administration of GHRP-1, a study reported identification of six GHRP-1 metabolites, and reported that the parent form of GHRP-1 was not detected in urine. (PMIDs: 25869809) [PMID 25869809]
In that same urine-metabolite study, GHRP-1 (2-4) free acid was reported to be detected in urine up to 27 hours after administration. (PMIDs: 25869809) [PMID 25869809]
Review sources reported that GHRPs are synthetic peptides that stimulate GH release and have no structural homology with GHRH, acting via specific receptors located at the pituitary and/or hypothalamic level; the exact mechanisms were stated to be unclear. (PMIDs: 9186261, 9465289, 8950613, 8) [PMID 9186261, 9465289, 8950613, 8496311]
A review source stated that hypotheses include that GHRPs could counteract somatostatinergic activity at the pituitary and hypothalamic level and/or act at least partially via a GHRH-mediated mechanism, while also noting that the possibility of action via an unknown hypothalamic factor remains open. (PMIDs: 9186261, 9465289, 8) [PMID 9186261, 9465289, 8496311]
Independent test grades
No independent third-party test data is available for GHRP-1 yet. Our test grades are aggregated from Finnrick, which independently tests a subset of research peptides — many approved drugs and newer or niche compounds aren't covered.
Research literature (10)
Consolidated from PubMed — each links to the original record.
Bowers CY · The Journal of pediatric endocrinology · 1993 · PMID 8374685
FAQ
What is GHRP-1?
GHRP-1 (39EVI31P0W, RefChem:110496, 141925-59-9) is classified under ghrelin / gh secretagogues, sold for research use only and not approved for human consumption. Research goals associated with it include gh axis support.
Is GHRP-1 FDA-approved?
No. GHRP-1 is sold for research use only and is not approved for human consumption.
What does the research on GHRP-1 say?
peptideone aggregates 10 references from PubMed for GHRP-1. The summary on this page digests them with citations; we summarize sources and make no efficacy claims.